We use essential cookies (authentication, your saved goals/stack) by default. With your permission we'll also enable privacy-respecting analytics (Vercel Web Analytics, anonymous load-time metrics) and error-replay diagnostics (Sentry — DOM snapshots only when an error fires) so we can fix bugs faster. Learn more about cookies
Pet3.2
Petrelintide Research
Mostly mechanism / observationalLimited safety
5 peer-reviewed studies
What the evidence says
Mostly mechanism / observational
Most Petrelintide studies are mechanism or observational rather than RCTs that measure a clinical effect — keep findings provisional.
Most evidence is from medium-quality randomised trials published 2021–2026 with a typical study size of 706 participants.
Based on 5 studies · 2 RCTs · 706 total participants
Confidence
Low
By outcome
Weight loss & obesity
Mostly mechanism / observational5 studies
Glucose & metabolic
Mostly mechanism / observational3 studies
Safety profile
Mostly mechanism / observational3 studies
Active research area
5 studies in the last 5 years
20212026
1RCTn=706 · large study2021
Mean percentage weight reductions from baseline were greater with all doses of cagrilintide (0·3-4·5 mg, 6·0%-10·8%) versus placebo (3·0%)... Weight reductions were also greater with cagrilintide 4·5 mg versus liraglutide 3·0 mg (10·8% vs 9·0%).
Lau DCW, Erichsen L, Francisco AM, Satylganova A, le Roux CW, McGowan B, Pedersen SD, Pietiläinen KH, Rubino D, Batterham RL. · Lancet (2021)
Phase-2, double-blind, randomised, placebo- and active-controlled dose-finding trial across 57 sites in ten countries; 706 adults with overweight/obesity (no diabetes) on once-weekly subcutaneous cagrilintide 0.3-4.5 mg vs liraglutide 3.0 mg vs placebo over 26 weeks
Mean weight loss ranged 6.0-10.8% across cagrilintide doses vs 3.0% placebo; the 4.5 mg dose modestly beat liraglutide 3 mg (10.8% vs 9.0%)
Gastrointestinal disorders (nausea, constipation, diarrhoea) and administration-site reactions were the most frequent adverse events; GI events 41-63% across doses vs 32% placebo
Petrelintide was slowly absorbed, had a half-life of ~10 days, showed steady-state dose proportionality, and reduced body weight by up to 8.6% after 16 weeks... appeared safe, had a low incidence of GI TEAEs, and resulted in clinically relevant weight loss.
Brændholt Olsen M, Griffin J, Hövelmann U, Macura S, Fredsted Hagen B, Hesse D, Heise T. · Diabetes Obes Metab (2026)
Petrelintide-specific. The pivotal early human dataset: two randomised, placebo-controlled, double-blind phase-1 trials (single ascending dose 0.04-2.4 mg SC plus a 0.35 mg IV dose; and multiple-ascending-dose once-weekly SC escalated to 2.4/4.8/9.0 mg) in normal/overweight adults and adults with overweight/obesity
Well tolerated with no serious or severe treatment-emergent adverse events; nausea was the most common GI event (16.7-33.3% petrelintide vs 16.7% placebo in MAD part 2), diarrhoea rare and vomiting only in the one participant who discontinued
Slowly absorbed with a ~10-day half-life (supporting once-weekly dosing) and steady-state dose proportionality; reduced body weight by up to ~8.6% after 16 weeks
Several recently developed long-acting amylin analogues have shown strong efficacy as monotherapy in clinical trials: these include eloralintide, petrelintide, Met-233 and AZD6234.
Bailey CJ, Flatt PR, Conlon JM. · Peptides (2026)
Amylin-class context, NOT petrelintide-specific outcome data. Review of long-acting amylin-related peptides for obesity and type 2 diabetes, covering pramlintide, cagrilintide/CagriSema, amycretin, and petrelintide
Names petrelintide among recently developed long-acting amylin analogues 'shown strong efficacy as monotherapy in clinical trials' — but the detailed evidence summarised is for the broader class
Describes the established amylin mechanism: central satiety induction, slowed gastric emptying, suppressed prandial glucagon; GI side effects (especially nausea) common during initiation and up-titration but mostly resolving
Herein, we report the development of petrelintide, a potent, stable, long-acting analogue of human amylin that can be formulated at about neutral pH... Petrelintide is in clinical development as a potential treatment for weight management.
Fischer Munch H, Just R, Mosolff Mathiesen J, Eriksson PO, Skodborg Villadsen J, Vestergaard B, Deryabina M, Demmer O, Skarbaliene J, Hamprecht DW, Rist W, Baader-Pagler T, Grube A, Heim-Riether A, Giehm L. · J Med Chem (2025)
Petrelintide-specific. Medicinal-chemistry discovery/development paper (Zealand Pharma with Boehringer Ingelheim) describing the design of petrelintide to overcome amylin's amyloid aggregation and short half-life
Engineered for chemical stability while retaining in vitro and in vivo potency, and formulable at near-neutral pH to enable potential co-formulation with other weight-management peptides
Establishes petrelintide as a stable long-acting human amylin analogue selected for clinical development in obesity
The article is a review of the emerging preclinical and clinical data regarding the application of peptide-based amylin receptor agonists... including pramlintide and cagrilintide... and investigational drugs, including ZP8396 and amycretin.
Rejili M, Hussain MS, Khan Y, Haouala F, Ganesan S, Sahoo S, Pal A, Arora V. · Vascul Pharmacol (2026)
Amylin-class context, NOT petrelintide-specific outcome data. Review of amylin-receptor agonists for obesity, including pramlintide, cagrilintide, KBP-series DACRAs, and investigational agents including ZP8396 (petrelintide) and amycretin
Details amylin-receptor (calcitonin-receptor + RAMP) molecular biology and central homeostatic/hedonic feeding control — the mechanistic foundation for the class
Frames ZP8396/petrelintide as an investigational agent within an emerging class with enhanced pharmacokinetics and GLP-1 synergy potential